The role of vasoactive agents in the resuscitation of microvascular perfusion and tissue oxygenation in critically ill patients
Boerma, C.; Ince, C.

Published in:
Intensive Care Medicine

DOI:
10.1007/s00134-010-1970-x

Citation for published version (APA):
Boerma, E. C., & Ince, C. (2010). The role of vasoactive agents in the resuscitation of microvascular perfusion and tissue oxygenation in critically ill patients. Intensive Care Medicine, 36(12), 2004-2018. DOI: 10.1007/s00134-010-1970-x
The role of vasoactive agents in the resuscitation of microvascular perfusion and tissue oxygenation in critically ill patients

Abstract  Purpose: The clinical use of vasoactive drugs is not only intended to improve systemic hemodynamic variables, but ultimately to attenuate derangements in organ perfusion and oxygenation during shock. This review aims (1) to discuss basic physiology with respect to manipulating vascular tone and its effect on the microcirculation, and (2) to provide an overview of available clinical data on the relation between vasoactive drugs and organ perfusion, with specific attention paid to recent developments that have enabled direct in vivo observation of the microcirculation and concepts that have originated from it.  Methods: A MedLine search was conducted for clinical articles in the English language over the last 15 years pertaining to shock, sepsis, organ failure, or critically ill patients in combination with vasoactive drugs and specific variables of organ perfusion/oxygenation (e.g., tonometry, indocyanine clearance, laser Doppler, and side-stream dark field imaging).  Results: Eighty original papers evaluating the specific relationship between organ perfusion/oxygenation and the use of vasoactive drugs were identified and are discussed in light of physiological theory of vasomotor tone.  Conclusions: Solid clinical data in support of the idea that increasing blood pressure in shock improves microcirculatory perfusion/oxygenation seem to be lacking, and such a concept might not be in line with physiological theory of microcirculation as a low-pressure vascular compartment. In septic shock no beneficial effect on microcirculatory perfusion above a mean arterial pressure of 65 mmHg has been reported, but a wide range in inter-individual effect seems to exist. Whether improvement of microcirculatory perfusion is associated with better patient outcome remains to be elucidated.

Keywords Organ perfusion · Oxygenation · Microcirculation · Vasoactive · Shock · Vasomotor tone

Introduction

Although shock is defined in terms of a critically low blood pressure, a more generally accepted and physiology-based definition of shock is: the inability of the circulation to sustain the cellular respiration needed to maintain normal organ function [1]. This controversy in definition reflects an underlying dilemma with profound effects at bedside. Although intensivists are aware of the physiology-based mechanisms of shock, they have to rely on surrogate global upstream (e.g., blood pressure) and/or downstream (e.g., SvO2) hemodynamic variables to
diagnose ‘inadequate’ organ perfusion and guide therapy. Attempts to integrate regional indicators such as intestinal CO₂, lactate and indocyanine green (ICG) clearance, which have all been associated with prognosis, have had limited success.

Apart from these general limitations, it becomes clear that in distributive shock shunting in the microcirculation is an intrinsic complexity. Although theoretically the concept of shunting has been well known for many decades [2], new technologies have elucidated the role of ‘microcirculatory weak units.’ In a model of ischemia reperfusion, a speckled pattern of NADH fluorescence and pO₂ emerged after re-oxygenation, indicating an inhomogeneous distribution of cells more vulnerable to ischemic insults than others. Microsphere embolization determined these so-called ‘weak units’ at the capillary level [3]. Provided upstream oxygen delivery is adequate, shunted parts of the microcirculation remain hypoxic in the presence of well-maintained venous pO₂, explaining the persistence of elevated lactate and regional pCO₂ levels [4] not sensed by the downstream variables such as SvO₂ [5]. The net systemic result is an inability to increase tissue oxygen uptake, despite efforts to ‘(supra)normalize’ oxygen delivery, but whether this reflects a true extraction deficit as result of a preceded cellular metabolic shutdown or a potentially correctable state of inhomogeneous hypo perfusion remains to be established [6]. Because of the introduction of direct in vivo observation of the microcirculation [7], heterogeneity of blood flow has now become a key feature of distributive shock. It has not only been reported within the microcirculation [8], but also between different organs, within different regions of one organ, in response to therapeutic interventions and in a time-dependent way [4, 9], all challenging the simplicity of systemic hemodynamic monitoring under such conditions.

At first evaluation, these observations seem to add more data to the already dazzling complexity of treatment modalities in the critically ill. However, these new insights have established two main findings: (1) the independent perfusion behavior of the microcirculation in relation to classically measured systemic hemodynamic variables, albeit within certain absolute limits of minimal perfusion pressure [8], and (2) persistence of microcirculatory alterations are associated with morbidity and mortality under various conditions, irrespective of correction of systemic hemodynamics [10, 11]. The issue to be resolved is whether correction of microcirculatory distributive alterations will improve organ function and morbidity. In order to explore this exiting concept, it is not sufficient to ‘simply’ find novel therapeutic approaches that specifically aim to reopen the microcirculation directly. We also have to be prepared to (re)evaluate our current strategies at the bedside in the light of its potential effects from the perspective of the microcirculation and relate it to organ function and outcome.

Administration of vasoactive compounds and fluid therapy are the cornerstone of hemodynamic management of critically ill patients. In this paper we will review reported effects of vasoactive substances on microcirculatory perfusion and tissue oxygenation in shock. These compounds have been advocated to improve systemic perfusion pressure and oxygen delivery, with subsequent improvement of tissue perfusion and oxygen uptake [12]. But do they behave the way we expect them to do? Since shock is a syndrome rather than a well-defined pathophysiologic entity, disease itself as well as treatment might contribute to the clinical picture [13]. An appreciation of basic physiology with respect to manipulating vascular tone and its effect on the microcirculation is followed by a systematic review of the literature. We will focus our review on recent clinical research that includes microcirculatory effects of three classes of vasoactive substances: vasopressors, inotropes and vasodilators, and follow the suggested classification of shock etiology [2]. Preclinical studies will only be discussed in so far as they pertain to the clinical studies.

Materials and methods

In MedLine the following search strategy was performed. Article titles containing shock or sepsis or septic or organ failure or critically ill in combination with vasopressor or vasoactive or inotrope or inotropic or vasodilator or several specific vasoactive drugs [e.g., (nor)adrenaline/(nor)epinephrine, vasopressin, dopamine, dobutamine, nitroglycerin] were selected. The search was restricted to clinical studies in the English language, published over the last 15 years, where indicators of microcirculatory or regional perfusion were specifically mentioned, or in case the effect was evaluated with aid of specific microcirculatory or regional techniques [e.g., tonometry/capnography, ICG, orthogonal polarization spectral (OPS)/side-stream dark field (SDF) imaging, spectrophotometry (Table 1)].

Results

Physiology

Microcirculatory perfusion pressure is the net result of precapillary inflow pressure minus venular outflow pressure. Most of the pressure drop occurs upstream in small arterioles (resistance vessels) as the principal site of active diameter changes to achieve regulation of blood flow. Mean capillary pressure is therefore much closer to venous pressure than to arterial pressure, which is relevant for the maintenance of tissue fluid balance [14].
| Technique                      | Principle                                                                 | Data expressed as                                      | Area of interest                                      | Remarks                                                                 |
|-------------------------------|---------------------------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|-------------------------------------------------------------------------|
| **Tonometry**                 | Balloon content (saline: tonometry, air: capnography) equilibrates with mucosal cellular fluid/gas. Content is quantified with classical bloodgas technology (pH, pCO₂, HCO₃⁻) | Intestinal pH or difference between intestinal and arterial (pCO₂ ᵃ⁻) | Mucosal capillary blood flow                                   | Detects mucosal dysoxia (imbalance between oxygen demand and supply) as a result of inadequate microvascular perfusion. Hypoxic hypoxia is not detected, serosal perfusion can influence measurements. |
| **Indocyanine green clearance** | Dye dilution method. The flow is related to the quantity of the injected indicator dye divided by the area under the curve of the downstream dye concentration, according to the Stewart-Hamilton equation | l/min                                                  | Hepatopancreatic vascular compartment                     | Indocyanine green clearance is dependent on overall hepatopancreatic blood flow and hepatic cellular blood flow function (altered in liver failure) |
| **Laser-Doppler flowmetry**   | Shift in frequency between emitted and received signal related to (red) blood cell velocity (Doppler principle); flow = velocity × probe catchment area | m/s (velocity) or l/min (flow)                          | Catchment volume incorporates arteriolar, capillary and venular blood flow | Hemoglobin saturation may be normal or elevated under conditions of microvascular heterogeneity in capillary blood flow due to shunting |
| **Spectrophotometry**         | Light with a specific wavelength is emitted by a spectrometer. Given a specific distance, the solute concentration or color between the spectrometer and the receiving photometer determines the (change in) received light intensity, according to Beer's law | Optical density units from which hemoglobin saturation (%) is calculated | Catchment area incorporates capillary and venular hemoglobin saturation | Hemoglobin saturation may be normal or elevated under conditions of microvascular heterogeneity in capillary blood flow due to shunting |
| **Orthogonal polarization spectral imaging** | Direct in vivo video microscopy. Absorbance of green light (540 nm) by hemoglobin projects red blood cells as black dots. Polarization prevents scattering of light | Semi-quantitative: microvascular blood flow index (convective transport) and perfused capillary density (diffusion distance) | Images less than 1 mm² discriminates between capillaries and venules | Visualization of vessels depends on presence of red blood cells. Enables to visualize distributive changes in blood flow between individual capillaries |
| **Sidestream dark field imaging** | Direct in vivo video microscopy. Absorbance of green light (540 nm) by hemoglobin projects red blood cells as black dots. Ring of stroboscopic light emitting diodes around the camera prevents scattering of light | Semi-quantitative: microvascular blood flow index (convective transport) and perfused capillary density (diffusion distance). Quantitative: functional capillary density (software analysis needed) | Images less than 1 mm² discriminates between capillaries and venules | Visualization of vessels depends on presence of red blood cells. Enables to visualize distributive changes in blood flow between individual capillaries |
Under normal conditions sympathetic vasoconstriction is reduced in case of venular hypoxia. This signal is forwarded upstream electrophysiologically via endothelial cells connected by gap junctions proximal to arterioles causing upstream dilatation. This process is regulated per microcirculatory unit arising from the respective arteriole feed vessels [15]. It is proposed that the ‘sensor’ for detecting changes in ambient $pO_2$ is located downstream and acts by release of nitric oxide (NO) in the venules [16]. In this respect additional exogenous precapillary and postcapillary vasoconstriction by means of a vasopressive drug results in a reduced net perfusion pressure over the microcirculation [17], despite increment of systemic blood pressure (Fig. 1). At the same time shunting may disrupt the normal venular signaling process for vasodilation to prevent local hypoxia. Indeed, in ischemia/reperfusion local hypoxia persists in ‘microcirculatory weak units’ after restoration of oxygen delivery in a speckled pattern that appears to be determined at the capillary level, but not at the arteriolar level [3].

Apart from interference in the complex regulation of tissue perfusion, vasoactive drugs may also influence the homeostasis of tissue oxygenation. Tissue oxygenation is not only dependent on convective properties of red blood cells (flow), but is also determined by diffusion. Given the gas-specific characteristics, oxygen diffusion is related to the pressure gradient and inversely related to the distance between the capillary and the cell (Fig. 2). Closing
capillaries in order to maintain perfusion pressure increases diffusion distance and vice versa. Under resting conditions capillaries constantly perform changes in caliber in order to serve both purposes [15].

A third factor that influences microcirculatory oxygen delivery is capillary hematocrit. Mechanical interaction between red blood cells and vessel walls induces the formation of a plasma layer adjacent to the wall and increases hematocrit in the center. Since blood flow-velocity distribution has a parabolic shape, from zero next to the wall to a maximum at the center, the average red cell velocity is higher than overall blood velocity. As a consequence, red cell transit time is reduced. This results in dynamic lowering of the capillary hematocrit in comparison to the entering and discharge hematocrit, and is known as the Fahraeus effect [18]. Additional to this effect, capillary hematocrit is also determined by a phenomenon, originally described by Krogh as ‘plasma skimming’ [19]. At the diverging branches of the capillary network, distribution of red cells is related to the diameter of the daughter vessels (Fig. 3). During in vitro experiments at a systemic hematocrit of 50%, capillary hematocrit ranged from 6.8% during vasoconstriction to 38% under vasodilatation [20], with profound implications on capillary oxygen transport. From the perspective of microcirculation, the dilemma of the use of vasopressors to enhance organ perfusion and oxygenation cannot be better expressed than in the original observations by Krogh: ‘This plasma skimming is usually very pronounced when adrenaline is applied in small drops to muscle arteries of which all branches, even the smallest, react and show a contraction, which in a short time may become complete. The portion of the muscle supplied by the contracting artery becomes blanched and the capillaries often disappear completely from view, while application of adrenaline to capillaries and venules alone shows that these vessels do not react visibly to the substance’ [19].

Despite abundant experimental data, little is known about human in vivo alterations of vasomotor tone during shock. Direct in vivo observations of the microcirculation in animal endotoxemia demonstrated loss of arterial vasomotion. Interestingly, not all vessels were affected at once, but areas with stagnant blood flow were observed next to areas with brisk flow [21]. In humans, topical endotoxin exposure produced acute venous hyporesponsiveness to NE or sympathetic nervous system activation. This was inhibited by glucocorticoids, but not mitigated by NO synthase- or cyclo-oxygenase inhibitors, suggesting other mediators than NO or prostanoids contribute to the overall vascular response to endotoxin [22]. Systemic LPS injection in healthy volunteers blunted the vascular baroreflex response against nitroprusside-induced hypotension and caused complete uncoupling of the cardiac baroreflex from prevailing blood pressure [23]. At present, no direct observations of the microcirculation, other than in tongue or skin, are available from human endotoxemia models.

Human studies
Vasopressors
Norepinephrine (α and β-adrenergic, Table 2) is the most commonly advocated vasopressive drug in septic shock to maintain mean arterial pressure (MAP) at a minimum level of 65 mmHg [12]. Although suggested, improvement of outcome as a result of the use of NE has never been established [24]. Recent studies, which included direct in vivo observation of the microcirculation with Sidestream Dark Field (SDF) imaging, have established that in human sepsis further increment of MAP above 65 mmHg by means of NE does not improve sublingual microcirculatory perfusion, intestinal pCO₂ concentrations or arterial lactate levels [25, 26]. This confirmed previous reports in which stepwise increases of MAP with

---

**Fig. 3** Under experimental conditions with a systemic hematocrit ($H_A$) of 50%, capillary hematocrit ($H_{cap}$) ranges from 6.8% under vasoconstriction to 38% under vasodilation. (From [20] by permission)
cumulating NE doses did not change arterial lactate levels, skin capillary blood flow, arterial-to-gastric $pCO_2$ gradient ($pCO_2_{g,a}$), systemic oxygen uptake or renal function [27, 28]. However, substantial inter-individual differences were observed, related to baseline values of microvascular blood flow [25]. Furthermore, these effects may be time and situation dependent [29], and equal changes in MAP may have different drug-related effects on organ perfusion [30]. For renal function an optimal MAP of 75 mmHg in sepsis has been suggested, but direct in vivo observations of the renal microcirculation has not been performed [31]. These studies underline the concept that under conditions of a minimal systemic perfusion pressure, an additional rise in arterial pressure does not automatically improve microcirculatory perfusion in distributive shock, in accordance with physiological theory [17]. Clearly, despite important efforts to compare mortality, systemic and regional perfusion and cardiovascular side effects between (combinations with) NE and other vasopressors, these studies do not elucidate its individual effects on the microcirculation or establish a critical minimum MAP with respect to microcirculatory organ perfusion [32–35].

An observed relation between both hypotension and mortality, as well as vasopressor load and mortality, may be related to the event itself, but may also be a marker for severity of illness [36, 37].

In cardiogenic shock, inotropic agents, but not vasopressors, are advocated [38, 39]. Intra-aortic balloon counter pulsation instantly improved sublingual microcirculatory blood flow in cardiogenic shock, but additional NE

### Table 2 Adrenergic vasopressors (summary of effects in human studies on microvascular perfusion, oxygenation and organ function)

| Study [ref] | Vasopressor | Setting | Technique(s) | Effects | Remarks |
|-------------|-------------|---------|--------------|---------|---------|
| [11, 25]    | Norepinephrine | Septic shock, $n = 20$, $n = 20$ | SDF-imaging, tonometry, laser-Doppler | No change in sublingual microvascular blood flow, lactate or $pCO_2_{g,a}$ | Stepwise increase MAP from 65 to 85 mmHg, individual effect baseline-dependent |
| [27]        | Norepinephrine | Septic shock, $n = 10$ | Laser-Doppler, tonometry | No difference in skin capillary blood flow, $pCO_2_{g,a}$ lactate or urine output | Stepwise increase MAP from 65 to 85 mmHg |
| [28]        | Norepinephrine | Septic shock, $n = 28$ | Creatinine clearance | No difference in lactate, urine output or creatinine clearance | Comparison between MAP 65 and 85 mmHg |
| [31]        | Norepinephrine | Septic shock, $n = 11$ | Doppler ultrasonography, creatinine clearance | Decrease in renal resistive index, increase in urine output, no change in creatinine clearance | Effect between MAP 65 and 75, no further change at 85 mmHg |
| [42]        | Epinephrine  | Septic shock, $n = 8$ | Tonometry, hepatic vein lactate, ICG clearance | Decrease in mucosal pH and splanchnic blood flow, increase in hepatic vein lactate | Cross-over, in addition to norepinephrine plus dobutamine |
| [34]        | Phenylephrine | Septic shock, $n = 32$ | Tonometry, ICG clearance | No change in splanchnic blood flow, $pCO_2_{g,a}$ lactate, urine output or creatinine clearance | Increment MAP from 65 to 75 mmHg, comparison between norepinephrine and phenylephrine |
| [44]        | Phenylephrine | Septic shock, $n = 15$ | Tonometry, ICG clearance | Decrease in splanchnic blood flow, $pCO_2_{g,a}$ lactate or creatinine clearance | Switching from norepinephrine to phenylephrine under steady state MAP at 70 mmHg |
| [45]        | Phenylephrine | Cardiopulmonary bypass, $n = 15$ | SDF-imaging, laser-Doppler flowmetry, spectrophotometry | Decrease in sublingual capillary blood flow together with an increase in microcirculatory hemoglobin oxygen saturation and overall sublingual blood flow, suggesting shunt | Increment MAP from 47 to 68 mmHg under steady state cardiac output |
| [74]        | Dopamine (high dose) | Septic shock, $n = 20$ | Tonometry | Decrease in gastric mucosal pH | Increment MAP from $\leq 60$ to $\geq 75$ mmHg, under norepinephrine intestinal pH decreased |

*SDF* Sidestream dark field, $pCO_2_{g,a}$ arterial-to-gastric $pCO_2$ gradient, MAP mean arterial pressure, ICG indocyanine green
dosage was inversely correlated with microcirculatory blood flow [40].

**Epinephrine** (α and β-adrenergic, Table 2) in the treatment of septic shock has been subject to controversy. Hyperlactatemia during use of epinephrine in sepsis treatment may be caused by tissue hypoxia, but may also be explained by direct metabolic effects [32, 41]. Human data about direct effects of epinephrine on microcirculatory perfusion in sepsis are not available, but only in comparison to NE. In a crossover design, in comparison to NE plus dobutamine, epinephrine was associated with lower intestinal pH (pH₃) and higher hepatic venous lactate levels under equal systemic hemodynamic conditions [42], but again interpretation of these data with respect to splanchnic perfusion is complicated by the intrinsic effect of epinephrine to cause hyperlactatemia and systemic acidosis [41, 43].

**Phenylephrine** (x-adrenergic, Table 2) has been used to increase MAP in human sepsis from 65 to 75 mmHg over a 12-h period [34]. Gastric-to-arterial pCO₂ difference, indocyanine clearance, arterial lactate levels and urine output/creatinine clearance were found to be unaltered over time and in comparison to NE, indicating that intestinal microcirculatory organ perfusion neither improved nor deteriorated as a result of a phenylephrine-induced rise in MAP. However, switching from NE to phenylephrine in patients with septic shock while maintaining MAP at 70 mmHg at steady-state systemic hemodynamic variables revealed a rise in pCO₂ g-a and a decrease in ICG clearance and urine output/creatinine clearance [44]. These indicators of impaired splanchnic and renal perfusion during phenylephrine infusion disappeared after switch-back to NE again.

In cardiopulmonary bypass (CPB)-induced hypotension, phenylephrine was used to increase MAP from 47 to 68 mmHg [45]. During hypotension, SDF-measured microcirculatory blood flow of sublingual capillaries was unchanged in comparison to pre-CPB hypotension, but after correction with phenylephrine microcirculatory blood flow was significantly reduced. At the same time, global tissue blood flow (laser Doppler) and spectrophotometric microvascular hemoglobin oxygen saturation (HbO₂) of the tongue increased, underlining the distributive changes that take place as a result of phenylephrine administration, not sensed in the absence of direct observation of the microcirculation. Interestingly, in an animal model of CPB-induced hypotension, administration of phenylephrine also reduced tissue perfusion to all visceral organs despite correction of MAP from 40 to 65 mmHg [46]. However, correction of hypotension by increasing pump flow improved perfusion of the pancreas, colon and kidneys.

**Vasopressin** (Table 3) depletion is believed to play a causative role in sepsis-induced vasodilatory shock [47]. In a mixed population with catecholamine-resistant vasodilatory shock, additional low-dose arginine vasopressin (AVP) was associated with an increment of pCO₂ g-a over time, but lower than NE alone [48]. Direct in vivo observation of the sublingual microcirculation with OPS imaging in a patient with non-septic distributive shock revealed marked microcirculatory alterations, which did not change after AVP injection [49]. In a randomized controlled open-label trial in patients with septic shock, additional use of AVP disclosed no changes in pCO₂ g-a and a higher creatinine clearance in comparison to NE alone [50]. This was in contrast to other reports of patients with septic shock; both additional continuous infusion of low dose AVP as well as replacement of NE by high dose AVP resulted in a significant increase of pCO₂ g-a [51, 52]. Equally conflicting data in animal studies are suggested to be related to volume status and cardiac performance [53]. AVP administration in sepsis has been associated with ischemic skin and tongue lesions in up to 30% [54], although in a recent trial the reported incidence was considerably lower and not different from norepinephrine [55].

In post-CPB cardiac surgery patients with high output failure, replacement of NE by AVP during steady-state MAP at 75 mmHg resulted in augmentation of pCO₂ g-a and diminished laser Doppler-measured jejunal mucosal perfusion, but this was in conjunction with a significantly lower cardiac index [56]. In hemodynamically stable post-CPB patients, incremental doses of AVP were associated with a decline in renal blood flow and impairment of the renal oxygen demand/supply relationship, in the absence of changes in MAP [57].

**Terlipressin** (Table 3) not only acts as a long-lasting prodrug for AVP with a high V1a receptor affinity, but is also a fast-acting vasopressor peptide per se that evokes coronary vasoconstriction with reduction in cardiac output [58]. It was originally described as rescue therapy in catecholamine-resistant septic shock [59]. The dilemma of its use in septic shock is outlined in a case report in which a bolus of terlipressin produced significantly higher MAP and urine output while tapering NE doses, but was also associated with a complete shutdown of sublingual microcirculatory perfusion and progressive acidosis [60]. More human data of direct effects of terlipressin on microcirculatory perfusion are not available, but only in comparison to other (combinations of) vasopressors. In septic shock after volume resuscitation, there was no difference between a bolus terlipressin or NE with respect to lactate levels and creatinine clearance [61]. Additional terlipressin to NE in septic shock was accompanied by a rise in bilirubin and aminotransferases [62], but not in pCO₂ g-a [63]. As with AVP, ischemic skin lesions are reported frequently [64].

With respect to splanchnic perfusion in relation to terlipressin, it is of note that it has become an established treatment modality in hepatorenal syndrome and gastrointestinal bleeding in liver cirrhosis. This condition is characterized by a marked vasoconstrictive state in the liver in combination with systemic vasoplegia. As
opposed to septic shock, its potent ability to reduce splanchnic blood flow has become beneficial under these conditions, either to increase risk of bleeding or to redirect flow to the kidney [65].

Inotropes

Dobutamine (predominantly $\beta_2$-adrenergic, Table 4) has both inotropic and mild vasodilatory effects. In an open-label setting addition of dobutamine in septic patients was associated with improved OPS-measured sublingual microcirculatory perfusion over time, irrespective of changes in systemic hemodynamic variables [66]. Interestingly, topical application of acetylcholine further improved microcirculatory perfusion, challenging the widespread concept of an irreversible endothelium in sepsis-induced hypotension. In a crossover setting, dobutamine attenuated intramucosal acidosis during sepsis, whereas dopamine did not change $pCO_2_{g-a}$ under equal effects in systemic hemodynamics [67]. Addition of dobutamine to NE in septic patients revealed a lower $pCO_2_{g-a}$, but no change in ICG plasma clearance [68, 69]; this could either be due to a direct effect on the microcirculation or a result of an increase in cardiac output. Whether an increase in general splanchnic perfusion indeed is followed by improved organ function is still a matter of debate [70].

Dopamine ($\beta_2$-adrenergic and dopaminergic, Table 4; in high-dose also $\alpha$-adrenergic, Table 2) was used in sepsis for many years in low concentrations for its potential beneficial effects on renal function as a result of afferent renal vessel dilatation. However, results of multiple studies have made such an effect of clinical relevance very unlikely [71]. Low-dose dopamine in addition to NE did not alter pH$_i$ despite increased overall splanchnic oxygen consumption [72, 73]. High-dose dopamine decreased pH$_i$ despite a rise in cardiac output, whereas NE increased pH$_i$ at the same MAP [74].

Dopexamine (predominantly dopaminergic, also $\beta_2$-adrenergic, Table 4) initially was introduced as an inotropic agent with specific pro splanchnic perfusion abilities [75]. However, though dopexamine infusion was associated with a partial correction of spectrophotometric gastric Hb$\Delta O_2$, $pCO_2_{g-a}$ remained unaltered [76]. This might be compatible with persistence of microcirculatory weak units

Table 3 Vasopressin and analogues (summary of effects in human studies on microvascular perfusion, oxygenation and organ function)

| Study [ref] | Vasopressor | Setting | Technique(s) | Effects | Remarks |
|-------------|-------------|---------|--------------|---------|---------|
| [48] AVP    | Vasodilatory shock, $n = 48$ | Tonometry | Increase in $pCO_2_{g-a}$ and bilirubin concentrations over time | Additional to 0.5 mcg/kg/min norepinephrine, MAP $\geq$ 70 mmHg; increase in $pCO_2_{g-a}$ lower in comparison to norepinephrine alone |
| [49] AVP    | Vasodilatory shock, $n = 1$ | OPS-imaging | No difference in capillary perfusion | Baseline capillary perfusion markedly impaired |
| [50] AVP    | Vasodilatory shock, $n = 23$ | Tonometry | No change in $pCO_2_{g-a}$ over time and in comparison to norepinephrine, no change in lactate, increase in creatinine clearance | In comparison to norepinephrine lower SOFA score, despite higher bilirubin |
| [51, 52] AVP | Septic shock, $n = 11, n = 12$ | Tonometry | Increase in $pCO_2_{g-a}$ | In addition to norepinephrine or replacement of norepinephrine respectively |
| [56] AVP    | Vasodilatory shock, post cardiac surgery, $n = 8$ | Tonometry, laser-Doppler flowmetry | Decrease in jejuna mucosal blood flow, increase in $pCO_2_{g-a}$ | No change in MAP, decrease in cardiac output |
| [57] AVP    | Vasodilatory shock, post cardiac surgery, $n = 8$ | Renal vein thermodilution, $^{51}$Cr-EDTA | Decrease in renal blood flow, increase in glomerular filtration rate, impairment of renal oxygen supply/demand relationship | No change in MAP |
| [60] Terlipressin | Septic shock, $n = 1$ | OPS-imaging | Complete shutdown sublingual microcirculatory blood flow, increase in urine output | Rise in MAP from 58 to 105 mmHg |
| [62, 63] Terlipressin | Septic shock, $n = 17, n = 15$ | Tonometry, laser-Doppler flowmetry | Increase of urine output and creatinine clearance, rise in bilirubin, no significant change in $pCO_2_{g-a}$ | |

AVP Arginine vasopressin, OPS orthogonal polarization spectral, $pCO_2_{g-a}$ arterial-to-gastric $pCO_2$ gradient, MAP mean arterial pressure, EDTA ethylenediaminetetraacetic acid
in combination with shunting, not sensed by spectrophotometry due to incorporation of arteriolar and venular hemoglobin. The same dilemma was illustrated in another study. Dopexamine, in addition to volume loading and dobutamine, increased ICG-derived splanchnic blood flow, but with a concomitant decrease in pHi [77]. Apart from this heterogeneity in blood flow between regional circulation and microcirculation, experimental data also suggested regional heterogeneity in blood flow between the gastric and colon region during the use of dopexamine in sepsis [78].

In postoperative cardiac surgery no difference in \( pCO_2_{g-a} \) between low-dose dopexamine and placebo could be detected [79]. In another study pH did not rise despite an increment in ICG-measured splanchnic blood flow and cardiac output [80]. Apart from thermogenetic effects of dopexamine, this might also be explained by a distributive effect. To date, in postoperative non-cardiac surgery, the use of dopexamine remains a matter of debate [81, 82].

**Levosimendan** (calcium sensitizer, Table 4) improves cardiac contractility and has slight vasodilatory effects. In patients with sepsis-induced myocardial depression levosimendan in addition to NE plus dobutamine was superior to an incremental dose of dobutamine, with respect to \( pCO_2_{g-a} \), laser Doppler-measured gastric mucosal perfusion, arterial lactate levels and creatinine clearance, either as a direct effect or as result of improved cardiac output [83]. After abdominal aortic aneurysm surgery \( pCO_2_{g-a} \) was lower in the levosimendan group in comparison to placebo, but despite a higher cardiac output this was not a result of better regional splanchnic perfusion [84]. In an experimental setting attenuation of sepsis-induced cellular hypoxia was observed, but simultaneous SDF-imaging failed to detect changes in microvascular blood flow [85].

**Vasodilators**

**Nitroglycerin** (NTG, Table 5) as well as other organic nitrates undergo intracellular metabolism in order to produce nitric oxide (NO)-mediated vasodilatation [86].

### Table 4 Inotropic agents (summary of effects in human studies on microvascular perfusion, oxygenation and organ function)

| Study [ref] | Inotope | Setting | Technique(s) | Effects | Remarks |
|-------------|---------|---------|--------------|---------|---------|
| [66]        | Dobutamine | Septic shock, \( n = 22 \) | OPS-imaging | Increase in sublingual capillary perfusion over time | Microcirculatory effects irrespective of systemic hemodynamics |
| [67–69]     | Dobutamine | Septic shock, \( n = 10, n = 14, n = 12 \) | Tonometry, laser-Doppler flowmetry, ICG clearance | Decrease in \( pCO_2_{g-a} \), increase in gastric mucosal perfusion, no change in overall hepatosplanchic perfusion | Substantial rise in cardiac output |
| [72, 73]    | Dopamine (low dose) | Septic shock, \( n = 11, n = 16 \) | Tonometry, ICG clearance | No change in intestinal pH despite increase in overall splanchnic blood flow | Effect on splanchic blood flow baseline-dependent |
| [76]        | Dopexamine | Septic shock, \( n = 15 \) | Tonometry, spectrophotometry | Increase in microvascular hemoglobin saturation, no change in intestinal pH | These combined observations suggest distributive failure |
| [77]        | Dopexamine | Septic shock, \( n = 22 \) | Laser-Doppler flowmetry | Increase in gastric mucosal blood flow | In addition to norepinephrine and in comparison to epinephrine |
| [79, 80]    | Dopexamine | Cardiac surgery, \( n = 19, n = 14 \) | Tonometry, ICG clearance | Increase in splanchnic blood flow and oxygen consumption, no change in intestinal pH | Significant rise in cardiac output |
| [83]        | Levosimendan | Septic shock, \( n = 28 \) | Tonometry, laser-Doppler flowmetry | Decrease in \( pCO_2_{g-a} \) and lactate, increase in gastric mucosal perfusion and urine output | In comparison to dobutamine |
| [84]        | Levosimendan | Abdominal aneurysm repair, \( n = 20 \) | Tonometry, ICG clearance | Overall splanchnic blood flow remained unaltered, \( pCO_2_{g-a} \) decreased | In comparison to placebo during aortic clamping, significantly higher cardiac output |

OPS Orthogonal polarization spectral, \( pCO_2_{g-a} \) arterial-to-gastric \( pCO_2 \) gradient, ICG indocyanine green
Despite the fact that overwhelming NO production is believed to play an important role in sepsis-induced hypotension, it has also been suggested as therapeutic strategy to overcome heterogeneity in microcirculatory blood flow [5, 87]. This dilemma is illustrated by the fact that unselective blocking of NO-synthase indeed was associated with a substantial increase in blood pressure, but also with a higher mortality [88, 89]. The general idea that increasing MAP results in a higher net microcirculatory perfusion pressure is not in line with physiological theory of the microcirculation as a low-pressure vascular compartment [17]. For example, in the brain of healthy volunteers (with intact autoregulation), NE was unable to increase estimated cerebral perfusion pressure despite a rise in MAP, whereas glyceryl trinitrate increased estimated cerebral perfusion pressure as a result of a lower zero flow pressure, even at a lower MAP [90].

In an uncontrolled setting, NTG was administered to septic patients who fulfilled static systemic hemodynamic resuscitation endpoints [91]. Despite fulfillment of these endpoints sublingual microcirculatory flow remained severely impaired. After a single bolus of NTG, instant improvement of microcirculatory blood flow was observed, indicating an NO-mediated endothelial ability for vasodilatation, which based on the analogy of topical acetylcholine challenged the general idea of endothelial hyporesponsiveness in sepsis-induced hypotension [66]. However, in a double-blind placebo-controlled setting, after fulfillment of dynamic systemic hemodynamic resuscitation endpoints, sublingual microcirculatory perfusion improved significantly over time, but no effect of NTG in comparison to placebo could be demonstrated [92]. In the uncontrolled setting, baseline values for microvascular blood flow in large vessels was considerably lower in comparison to the controlled setting, suggesting marked differences in systemic volume status. In cardiogenic shock, impairment of sublingual microcirculation has also been observed and associated with morbidity and mortality [93]. Application of low-dose NTG in addition to standard care for cardiogenic shock was associated with a rise in sublingual perfused capillary density [94]. This was not accompanied by a change in cardiac output or MAP and disappeared after cessation of NTG administration. Interestingly, non-pulsatile systemic circulatory flow support by means of a percutaneous left ventricular assist device after acute myocardial infarction was also reflected in a better sublingual microcirculatory flow score [95].

In the specific setting of gastric tube reconstruction, topical application of NTG improved laser Doppler blood flow in the fundus without changes in local HbiO2 [96]. However, no effect was observed during intravenous NTG in the same setting, suggesting potential interference with bioactivation [97].

**Ketanserin** (serotonin 5-HT2 antagonist and weak α1-adrenergic blocker, Table 5) has been used in the treatment of hypertension with a reported beneficial effect on microhemodynamics and hemorheology due vasodilatation and inhibition of platelet aggregation [98]. Administration of ketanserin in hypertensive post-CPB cardiac surgery patients effectively lowered MAP, while sublingual capillary blood flow was preserved [99].

---

**Table 5** Vasodilators (summary of effects in human studies on microvascular perfusion, oxygenation and organ function)

| Study [ref] | Inotrope | Setting | Technique(s) | Effects | Remarks |
|-------------|----------|---------|--------------|---------|---------|
| [91]        | Nitroglycerin | Septic shock, n = 8 | OPS-imaging | Instantaneous increase in sublingual microcirculatory blood flow after a 0.5 mg iv bolus | Open label, after fulfilment of static pressure resuscitation endpoint |
| [92]        | Nitroglycerin | Septic shock, n = 70 | SDF-imaging | No difference in sublingual microcirculatory blood flow after 24 h | Placebo controlled double-blind, after fulfilment of dynamic resuscitation endpoints. Effect ceased after stop medication |
| [94]        | Nitroglycerin | Cardiogenic shock, n = 20 | SDF-imaging | Increase in sublingual perfused capillary density and microvascular blood flow | MAP dropped from 86 to 68 mmHg |
| [99]        | Ketanserin | Cardiac surgery, n = 6 | SDF-imaging | No change in sublingual perfused capillary density | Intravenous ketanserin |
| [102]       | Prostacyclin | Septic shock, n = 16 | Tonometry | Increase in gastric mucosal pH | Patients with septic shock and pulmonary hypertension, aerosolized prostacyclin; effects in comparison to baseline and inhaled nitric oxide |
| [103]       | Prostacyclin | Septic shock, n = 16 | Tonometry, ICG clearance | Decrease in pCO2 g-a, no change in overall splanchnic perfusion | |

OPS Orthogonal polarization spectral, SDF sidestream dark field, pCO2 g-a arterial-to-gastric pCO2 gradient, ICG indocyanine green, MAP mean arterial pressure.


Prostacyclin (cyclic adenosine monophosphate activator, Table 5) was initially propagated as a drug for improvement of oxygen extraction deficits, suspected to cause tissue dyoxia [100]. Since then it has been studied extensively, especially in experimental settings, for its potential beneficial effect on organ perfusion, as it plays a crucial role in the physiological endothelial vasodilatory response to ischemia/reperfusion [101]. Administration of intravenous prostacyclin after conventional resuscitation was associated with higher pH and indicative for outcome [102]. Similar effects on pH were reported during aerosolized prostacyclin despite unaltered ICG clearance in patients with pulmonary hypertension [103].

During CPB, infusion of prostacyclin blunted jejunal vasomotion, resulting in a reduced ability to maintain laser Doppler-measured jejunal perfusion constant under variation of blood pressure (autoregulation) [104]. On the other hand, jejunal perfusion increased significantly in parallel to a drop in MAP, but unfortunately $p$CO$_2$ g-a was not measured to establish the overall effect on jejunal microcirculatory perfusion.

Conclusions

Regardless of practical limitations, there is a growing perception that shock should be defined at the level of the microcirculation. Previous clinical research was limited to surrogate markers of organ microcirculatory blood perfusion such as tonometry, laser Doppler flowmetry and ICG clearance. Recent developments have brought direct in vivo observation of the microcirculation in critically ill patients within reach, albeit limited to accessible organs. To date there are no data available in support of the idea that increasing MAP is beneficial from the perspective of microcirculatory perfusion and/or oxygenation, and such an idea is not in line with the physiological theory of the microcirculation as a low-pressure vascular compartment.

In septic shock several reports have demonstrated an absence of effect on microcirculatory perfusion above a MAP of 65 mmHg, but a lower threshold has not been established. The role of vasodilators in sepsis as a therapeutic strategy to recruit ‘microcirculatory weak units’ is yet to be elucidated. In cardiogenic shock neither vaso-pressors nor inotropic agents have been proven beneficial in terms of organ perfusion, but increasing systemic flow by means of several assist devices are now associated with better microcirculatory flow.

Acknowledgments We thank M. Koopmans and C. Kesting for their assistance in the design of Fig. 2

Conflict of interest ECB has no conflict of interest. CI holds a patent on SDF imaging, has stock in Microvision Medical and has received educational grants from Hutchinison Technology, Baxter, Novartis and Eli Lilly.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Vincent JL. International Sepsis Forum (2001) Hemodynamic support in septic shock. Intensive Care Med 27(Suppl 1):S80–S92
2. Weil MH, Shubin H (1971) Proposed reclassification of shock states with special reference to distributive defects. Adv Exp Med Biol 23:13–23
3. Ince C, Ashruf JF, Avontuur JA, Wieringa PA, Spaan JA, Bruining HA (1993) Heterogeneity of the hypoxic state in rat heart is determined at capillary level. Am J Physiol 264:H294–H301
4. Dubin A, Edul VSK, Pozo MO et al (2008) Persistent villi hypoperfusion explains intramucosal acidosis in sheep endotoxemia. Crit Care Med 36:535–542. doi:10.1097/01.CCM.0000300083.74726.43
5. Buwalda M, Ince C (2002) Opening the microcirculation: can vasodilators be useful in sepsis? Intensive Care Med 28:1208–1217. doi:10.1007/s00134-002-1407-2
6. Mongardon N, Dyson A, Singer M (2009) Is MOF an outcome parameter or a transient, adaptive state in critical illness? Curr Opin Crit Care 15:431–436. doi:10.1097/MCC.0b013e3283307a3b
7. Groner W, Winkelman JW, Harris AG, Ince C, Bouma GJ, Messmer K, Nadeau RG (1999) Orthogonal polarization spectral imaging: a new method for study of the microcirculation. Nat Med 5:1209–1212. doi:10.1038/13529
8. Trzeciak S, Dellinger RP, Parrillo JE et al (2007) Early microcirculatory perfusion derangements in patients with severe sepsis and septic shock: relationship to hemodynamics, oxygen transport, and survival. Ann Emerg Med 49:88–98, 98.e1–2. doi:10.1016/j.annemergmed.2006.08.021
9. Boerma EC, van der Voort PHJ, Spronk PE, Ince C (2007) Relationship between sublingual and intestinal microcirculatory perfusion in patients with abdominal sepsis. Crit Care Med 35:1055–1060. doi:10.1097/01.CCM.0000259527.89927.F9
10. Sakr Y, Dubois MJ, De Backer D, Creteur J, Vincent JL (2004) Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med 32:1825–1831
11. Jhanji S, Lee C, Watson D, Hinds C, Pearse RM (2009) Microvascular flow and tissue oxygenation after major abdominal surgery: association with post-operative complications. Intensive Care Med 35:671–677, doi:10.1007/s00134-008-1325-z
12. Dellinger RP, Levy MM, Carlet JM et al (2008) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 34:17–60. doi:10.1007/s00134-007-0934-2

13. Ince C (2005) The microcirculation is the motor of sepsis. Crit Care 9(Suppl 4): S13–S19. doi:10.1186/cc3753

14. Pries AR, Secomb TW, Gaethgens P (1996) Biophysical aspects of blood flow in the microvasculature. Cardiovasc Res 32: 654–667

15. Segal SS (2005) Regulation of blood flow in the microcirculation. Microcirculation 12:33–45. doi:10.1080/10739805908950280

16. Stamlar JS, Lai J, Eu JP, McMahon TJ, Demchenko JT, Bonaventura J, Gernert K, Plantadosi CA (1997) Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient. Science 276:2034–2037

17. Taylor AE, Moore TM (1999) Capillary fluid exchange. Am J Physiol 277: S203–S210

18. Sturner V, Sturk A (1989) Regulation of microcirculatory blood flow. Am J Physiol 257: H1233–H1241

19. Krogh A (1921) Studies on the physiology of capillaries: II. The reactions to local stimuli of the blood vessels in the skin and web of the frog. J Physiol 55: 412–422

20. Duling BR, Desjardins C (1987) Capillary hematocrit—what does it mean. News Physiol Sci 1987: 66–69

21. Delaunay A, Lebrun J, Delaunay M (1929) Le mode d’action des endotoxines bactériennes IV. Les troubles vaso-moteurs chez les animaux intoxiqués et leurs conséquences. J Physiol Paras 40: 39–110

22. Bhagat K, Collier J, Vallance P (1996) Local venous responses to endotoxin in humans. Circulation 94:490–497

23. Sayk F, Vieetheer A, Schaaf B, Wellhoener P, Weitz G, Lehnert H, Dott C (2008) Endotoxemia causes central downregulation of sympathetic vasomotor tone in healthy humans. Am J Physiol Regul Integr Comp Physiol 295: R891–R898. doi:10.1152/ajpregu.00444.2008

24. Martin C, Viviani X, Leone M, Thrion X (2000) Effect of norepinephrine on the outcome of septic shock. Crit Care Med 29: 276–282

25. Dubin A, Pozo MO, Casabella CA, Palizas F, Murias G, Moseinco MC, Kanoone Edul VS, Estenssoro E, Ince C (2009) Increasing arterial blood pressure with norepinephrine does not improve microcirculatory blood flow: a prospective study. Crit Care 13: R92. doi:10.1186/cc7922

26. Jhanji S, Stirling S, Patel N, Hinds CJ, Pearce RM (2009) The effect of increasing doses of norepinephrine on tissue oxygenation and microvascular flow in patients with septic shock*. Crit Care Med 37: 1961–1966. doi:10.1097/CCM.0b013e3181a0014c

27. LeDoux D, Astiz ME, Carpati CM, Rackow EC (2000) Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care Med 28: 2729–2732

28. Bourgoin A, Leone M, Delmas A, Garner F, Albanèse J, Martin C (2005) Increasing mean arterial pressure in patients with septic shock: effect assessed by variables and renal function. Crit Care Med 33: 780–786

29. Albanèse J, Leone M, Garner F, Bourgoin A, Antonini F, Martin C (2004) Renal effects of norepinephrine in septic and nonseptic patients. Chest 126: 534–539. doi:10.1378/chest.126.2.534

30. Nakajima Y, Baudry N, Duranteau J, Vicaut E (2006) Effects of vasopressin, norepinephrine, and L-arginine on intestinal microcirculation in endotoxemia. Crit Care Med 34: 1752–1757. doi:10.1097/CCM.0000218812.73741.6C

31. Derudder S, Cheisson G, Mazoit JX, Deruddre S, Cheisson G, Mazoit JX (2006) Effect of vasopressin on the microcirculation in septic and non-septic patients during cardiopulmonary bypass. Br J Anaesth 96: 424–429. doi:10.1093/bja/aal238

32. Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J, CAT Study investigators (2009) Acute microflow changes after stop and restart of intra-aortic balloon pump in cardiogenic shock. Intensive Care Med 35:1225–1233. doi:10.1007/s00134-009-1994-1

33. Levy B, Gibot S, Franck P, Cravoisy A, Boliaert PE (2005) Relation between muscle Na+–K+ ATPase activity and raised lactate concentrations in septic shock: a prospective study. Lancet 365: 871–875. doi:10.1016/S0140-6736(05)71045-X

34. De Backer D, Biston P, Devriendt J et al (2010) Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362: 779–789. doi:10.1056/NEJMoa0907118

35. Dünser MW, Takala J, Ulmer H et al (2009) Arterial blood pressure during early sepsis and outcome. Intensive Care Med 35: 1225–1233. doi:10.1007/s00134-009-1427-2

36. Dünser MW, Ruokonen E, Pettilä V, Ulmer H, Torgersen C, Schmittinger CA, Jakob S, Takala J (2009) Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial. Crit Care 13: R181. doi:10.1186/cc8167

37. Spahn DR, Cerny V, Coats TJ et al (2007) Management of bleeding following major trauma: a European guideline. Crit Care 11: R7. doi:10.1186/cc5868

38. Owca RM, Fox JT, Khan IA (2008) Cardiogenic shock: basics and clinical considerations. Int J Cardiol 123: 221–228. doi:10.1016/j.ijcard.2006.03.099

39. Jung C, Rödiger C, Fritzenwanger M, Schummi J, Lauten A, Figulla HR, Ferrante M (2009) Acute microflow changes after stop and restart of intra-aortic balloon pump in cardiogenic shock. Clin Res Cardiol 98: 469–475. doi:10.1007/s00392-009-0018-0

40. Levy B, Gibot S, Franck P, Cravoisy A, Boliaert PE (2005) Relation between muscle Na+–K+ ATPase activity and raised lactate concentrations in septic shock: a prospective study. Lancet 365: 871–875. doi:10.1016/S0140-6736(05)71045-X

41. Meier-Hellmann A, Reinhart K, Bredle DL, Specht M, Smolka JP, Hannemann L (1997) Epinephrine impairs splanchic perfusion in critically ill patients. Intensive Care Med 23: 399–404

42. Uusaro A, Takala J (1998) Vasoactive drugs and splanchic perfusion in septic shock. Crit Care Med 26: 1458–1460

43. Morelli A, Lange M, Ertmer C et al (2009) Short-term effects of phenylephrine on systemic and regional hemodynamics in patients with septic shock: a crossover pilot study. Shock 29: 446–451. doi:10.1097/shk.0b013e31815810ff

44. Maier S, Hasibeder WR, Hengl C, Pajk W, Schwarz B, Margreiter J, Hannemann L, Uhlig M, Torgersen C, Schmittinger CA, Jakob S, Takala J (2009) Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial. Crit Care 13: R181. doi:10.1186/cc8167
46. O’Dwyer C, Woodson LC, Conroy BP, Lin CY, Deyo DJ, Uchida T, Johnston WE (1997) Regional perfusion abnormalities with phenylephrine during normothermic bypass. Ann Thorac Surg 63:728–735

47. Landry DW, Oliver JA (2001) The pathogenesis of vasodilatory shock. N Engl J Med 345:588–595

48. Dünser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR (2003) Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 107:2313–2319. doi:10.1161/CIRCULATIONAHA.106.0006692.71008.BB

49. Dubois MJ, De Backer D, Creteur J, Anane S, Vincent JL (2003) Effect of vasopressin on sublingual microcirculation in a patient with distributive shock. Intensive Care Med 29:1020–1023. doi:10.1007/s00134-003-1742-y

50. Lauzier F, Lévy B, Lamarre P, Lesur O (2006) Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Med 32:1797–1803. doi:10.1007/s00134-006-0378-0

51. van Haren FMP, Rozendaal FW, van der Hoeven JG (2003) The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock. Chest 124:2256–2260

52. Klimzing S, Simon M, Reinhart K, Bredle DL, Meier-Hellmann A (2003) High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 31:2646–2650. doi:10.1097/01.CCM.0000094260.05266.F4

53. Van der Bracht H, Radermacher P (2008) Impact of vasopressin analogues on the gut mucosal microcirculation. Best Pract Res Clin Anaesthesiol 22:351–358

54. Dünser MW, Mayr AJ, Tür A, Pajk W, Barbara F, Knotzer H, Ulmer H, Hasibeder WR (2003) Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med 31:1394–1398. doi:10.1097/01.CCM.0000095722.94182.79

55. Russell JA, Walley KR, Singer J et al (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358:877–887. doi:10.1056/NEJMoa073737

56. Nygren A, Thörén A, Ricksten SE (2009) Vasopressin decreases intestinal mucosal perfusion: a clinical study on cardiac surgery patients in vasodilatory shock. Acta Anaesthesiol Scand 53:581–588. doi:10.1111/j.1399-6576.2008.01900.x

57. Bragadottir G, Redfors B, Nygren A, Sjellgren J, Ricksten SE (2009) Low-dose vasopressin increases glomerular filtration rate, but impairs renal oxygenation in post-cardiac surgery patients. Acta Anaesthesiol Scand 53:1052–1059. doi:10.1111/j.1399-6576.2009.02037.x

58. Rykvaert F, Verslyv A, Fort A, Murat B, Richard S, Guillot G, Colson PH (2009) Terlipressin, a vasopressin drug exhibits direct vasoconstrictor properties: consequences on heart perfusion and performance. Crit Care Med 37:876–881. doi:10.1097/CCM.0b013e3181b8199

59. O’Brien A, Clapp L, Singer M (2002) Terlipressin for norepinephrine-resistant septic shock. Lancet 359:1209–1210. doi:10.1016/S0140-6736(02)08225-9

60. Boerma EC, van der Voort PH, Nijdam F, van den Berghe GH (2003) Terlipressin in catecholamine-resistant septic shock patients. Shock 20:597–604. doi:10.1197/01.CCM.0000059722.71008.BB

61. Du¨ nser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR (2003) Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 107:2313–2319. doi:10.1161/CIRCULATIONAHA.106.0006692.71008.BB

62. De Backer D, Creteur J, Dubois MJ, Sakr Y, Koch M, Verdant C, Vincent JL (2006) The effects of dopamine on microcirculatory alterations in patients with septic shock are independent of its systemic effects. Crit Care Med 34:403–408

63. Neveire R, Mathieu D, Chagnon JL, Lebleu N, Wattel F (1996) The contrasting effects of dobutamine and dopamine on gastric mucosal perfusion in septic patients. Am J Respir Crit Care Med 154:1684–1688

64. Joly LM, Monchi M, Cariou A, Chiche JD, Bellenfant F, Brunet F, Dhainaut JP (1999) Effects of dopamine on gastric mucosal perfusion and hepatic metabolism in patients with septic shock. Am J Respir Crit Care Med 160:1983–1986

65. Döhler KD, Meyer M (2008) Vasopressin analogues in the treatment of hepatorenal syndrome and gastrointestinal haemorrhage. Best Pract Res Clin Anaesthesiol 22:335–350

66. De Backer D, Creteur J, Dubois MJ, Sakr Y, Koch M, Verdant C, Vincent JL (2006) The effects of dopamine on microcirculatory alterations in patients with septic shock are independent of its systemic effects. Crit Care Med 34:403–408

67. Neveire R, Mathieu D, Chagnon JL, Lebleu N, Wattel F (1996) The contrasting effects of dobutamine and dopamine on gastric mucosal perfusion in septic patients. Am J Respir Crit Care Med 154:1684–1688

68. Joly LM, Monchi M, Cariou A, Chiche JD, Bellenfant F, Brunet F, Dhainaut JP (1999) Effects of dopamine on gastric mucosal perfusion and hepatic metabolism in patients with septic shock. Am J Respir Crit Care Med 160:1983–1986

69. Duranteau J, Sibton P, Teboul JL, Vicaut E, Anguel N, Richard C, Samii K (1999) Effects of epinephrine, norepinephrine, or the combination of norepinephrine and dopamine on gastric mucosa in septic shock. Crit Care Med 27:893–900

70. Reinelt H, Radermacher P, Fischer G, Geisser W, Wachter U, Wiedeck H, Georgiieff M, Vogt J (1997) Effects of a dobutamine-induced increase in splanchnic blood flow on hepatic metabolic activity in patients with septic shock. Anesthesiology 86:818–824

71. Deaveye YA, Van den Berghe GH (2004) Is there still a place for dopamine in the modern intensive care unit? Anesth Analg 98:461–468

72. Meier-Hellmann A, Bredle DL, Specht A, Nashold BS (2004) The effects of low-dose dopamine on splanchnic blood flow and oxygen uptake in patients with septic shock. Intensive Care Med 30:23–30

73. Olson D, Pohlman A, Hall JB (1996) Administration of low-dose dopamine to nonoliguric patients with sepsis syndrome does not raise intramucosal gastric pH nor improve creatinine clearance. Am J Respir Crit Care Med 154:1664–1670

74. Marik PE, Mohedin M (1994) The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 272:1354–1357
75. Smithies M, Yee TH, Jackson L, Beale R, Bihari D (1994) Protecting the gut and the liver in the critically ill: effects of dopexamine. Crit Care Med 22:789–795
76. Temmesfeld-Wollbrück B, Szalay A, Mayer K, Olschewski H, Seeger W, Grimmelinger F (1998) Abnormalities of gastric mucosal oxygenation in septic shock: partial responsiveness to dopexamine. Am J Respir Crit Care Med 157:1856–1592
77. Seguin P, Laviolle B, Guinet P, Morel I, Malléclant Y, Bellissant E (2006) Dopexamine and norepinephrine versus epinephrine on gastric perfusion in patients with septic shock: a randomized study [NCT00134212]. Crit Care 10:R32. doi:10.1186/cc4827
78. Tenhunen JJ, Martikainen TJ, Uusaro A, Ruokonen E, Takala J (2004) Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 114-002). Crit Care Med 32:1–12. doi:10.1097/01.CCM.0000105581.01815.C6
79. Gärdebäck M, Settergren G, Ohquist G, Tirén C (1995) Effect of dopexamine on calculated low gastric intramucosal pH following valve replacement. Acta Anaesthesiol Scand 39:596–602
80. Uusaro A, Ruokonen E, Takala J (1995) Gastric mucosal pH does not reflect changes in splanchic blood flow after cardiac surgery. Br J Anaesth 74:149–154
81. Pearse RM, Belsey JD, Cole JN, Bennett ED (2008) Effect of dopexamine infusion on mortality following major surgery: individual patient data meta-regression analysis of published clinical trials. Crit Care Med 36:1323–1329. doi:10.1097/01.CCM.0000105118.66983.19
82. Morelli A, De Castro S, Teboul JL et al (2005) Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 31:638–644. doi:10.1007/s00134-005-2619-z
83. Leppikangas H, Tenhunen JJ, Lindgren L, Saleunis JP, Ruokonen E (2008) Effects of levosimendan on indocyanine green plasma disappearance rate and the gastric mucosal-arterial pCO2 gradient in abdominal aortic aneurysm surgery. Acta Anaesthesiol Scand 52:785–792. doi:10.1111/j.1399-6576.2008.01659.x
84. Fries M, Ince C, Rossaint R, Bleilevens C, Bickenbuch J, Rex S, Mik EG (2008) Levosimendan but not norepinephrine improves microvascular oxygenation during experimental septic shock. Crit Care Med 36:1886–1891. doi:10.1097/CCM.0b013e31817cedee9
85. Bihari D, Smithies M, Gimson A, van Bommel J, Tenhunen JJ, Martikainen TJ, Uusaro A, Ruokonen E, Takala J (2009) Low-dose nitroglycerin improves microcirculation in hospitalized patients with acute heart failure. Eur J Heart Fail 11:386–390. doi:10.1093/eurjhf/hfp021
86. Lam K, Sjaauw KD, Henrigues JPS, Ince C, de Mol BA (2009) Improved microcirculation in patients with an acute ST-elevation myocardial infarction treated with the Impella LP2.5 percutaneous left ventricular assist device. Clin Res Cardiol 98:311–318. doi:10.1007/s00392-009-0006-4
87. Bihari D, Smithies M, Gimson A, van Bommel J, Tenhunen JJ, Martikainen TJ, Uusaro A, Ruokonen E, Takala J (2005) The effect of nitroglycerin on microvascular perfusion and oxygenation during gastric tube reconstruction. Anesth Analg 100:1071–1117. doi:10.1213/01.ANE.0000317427.40592.6c
88. Bihari D, Smithies M, Gimson A, van Bommel J, Tenhunen JJ, Martikainen TJ, Uusaro A, Ruokonen E, Takala J (2005) Intraoperative nitroglycerin does not preserve gastric microcirculation during gastric tube reconstruction: a randomized controlled trial. Crit Care 10:R131. doi:10.1186/cc5043
89. Konishi M, Sakakura M, Tsushima N (1990) Effects of ketanserin on microhemodynamics and hemorheology in patients with essential hypertension. Cardiovasc Drugs Ther 4 Suppl 1:101–104
90. Klingsers PWG, Ozdemir A, van IJserna M, van Dongen EPA, Ince C (2009) Microcirculatory imaging in cardiac anesthesia: ketanserin reduces blood pressure but not perfused capillary density. J Cardiothorac Vasc Anesth 23:95–101. doi:10.1053/j.jvca.2008.09.013
91. Bihari D, Smithies M, Gimson A, Tinker J (1987) The effects of vasodilatation with prostacyclin on oxygen delivery and uptake in critically ill patients. N Engl J Med 317:397–403
92. Scheeren T, Radermacher P (1997) Prostacyclin (PGI2): new aspects of an old substance in the treatment of critically ill patients. Intensive Care Med 23:146–158
102. Radermacher P, Buhl R, Santak B, Klein M, Kniemeyer HW, Becker H, Tarnow J (1995) The effects of prostacyclin on gastric intramucosal pH in patients with septic shock. Intensive Care Med 21:414–421

103. Eichelbrö putter O, Reinelt H, Wiedeck H, Meződy M, Rossaint R, Georgieff M, Radermacher P (1996) Aerosolized prostacyclin and inhaled nitric oxide in septic shock—different effects on splanchnic oxygenation? Intensive Care Med 22:880–887

104. Nygren A, Thorén A, Houltz E, Ricksten SE (2006) Autoregulation of human jejunal mucosal perfusion during cardiopulmonary bypass. Anesth Analg 102:1617–1622. doi: 10.1213/01.ANE.0000219596.34753.72